Akari Therapeutics (AKTX) News Today $0.97 -0.03 (-2.99%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Akari Therapeutics Announces Key Leadership AppointmentsDecember 18 at 8:51 AM | globenewswire.comAkari Therapeutics Appoints Torsten Hombeck as CFODecember 17, 2024 | markets.businessinsider.comAkari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial OfficerDecember 16, 2024 | globenewswire.comAkari Therapeutics Announces Leadership RestructuringDecember 14, 2024 | markets.businessinsider.comStockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)December 14, 2024 | americanbankingnews.comEuropean Equities Traded in the US as American Depositary Edge Lower in Thursday TradingDecember 12, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Decline in Wednesday TradingNovember 20, 2024 | msn.comAkari Therapeutics regains full Nasdaq comlianceNovember 20, 2024 | markets.businessinsider.comAkari Therapeutics Plc: Akari Therapeutics Regains Full Nasdaq ComplianceNovember 19, 2024 | finanznachrichten.deAkari Therapeutics Regains Full Nasdaq ComplianceNovember 19, 2024 | markets.businessinsider.comAkari Therapeutics Advances Post-Merger with Strategic MovesNovember 16, 2024 | markets.businessinsider.comThis Akari Therapeutics Insider Increased Their Holding By 69% Last YearNovember 16, 2024 | finance.yahoo.comAkari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak BioNovember 14, 2024 | globenewswire.comAkari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. MergerNovember 8, 2024 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Monday TradingNovember 5, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise Slightly Higher in Thursday TradingOctober 24, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Nudge Lower in Tuesday TradingOctober 22, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Move Slightly Higher in Thursday TradingOctober 18, 2024 | msn.comAkari Therapeutics (NASDAQ:AKTX) Stock Quotes, Forecast and News SummaryOctober 12, 2024 | benzinga.comPVL: Lacsina, Soltones make it clear: Job's not done for AkariAugust 27, 2024 | msn.comPVL: Lethal 1-2-3 punch has made Akari untouchableAugust 27, 2024 | msn.comPVL: Taka Minowa relieved to steer Akari to breakthrough semisAugust 27, 2024 | msn.comAkari Therapeutics Reports Second Quarter 2024 Financial Results and Recent HighlightsAugust 19, 2024 | globenewswire.comAkari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic AtrophyAugust 19, 2024 | globenewswire.comPVL: Akari closes in on prelims sweep, turns back NxledAugust 15, 2024 | msn.comUnbeaten Akari slowly perfecting mindsetAugust 13, 2024 | msn.comPVL: Okaro switches to ‘destroy mode’ for AkariJuly 24, 2024 | msn.comPVL: Oly Okaro, Akari send Choco Mucho to 0-2 startJuly 23, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Lower Friday; Set to End Week Down 4%July 19, 2024 | msn.comAkari Therapeutics Reports First Quarter 2024 Financial Results and Recent HighlightsMay 16, 2024 | finance.yahoo.comAkari Therapeutics Reports First Quarter 2024 Financial Results and Recent HighlightsMay 16, 2024 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday TradingMay 2, 2024 | msn.comAkari gains despite leadership change amid portfolio shakeupMay 1, 2024 | msn.comAkari Therapeutics Appoints Samir Patel Interim CEO After CEO Rachelle Jacques Steps DownMay 1, 2024 | markets.businessinsider.comSamir R. Patel, M.D. Appointed Interim CEO for Akari TherapeuticsMay 1, 2024 | globenewswire.comAkari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger EntityMay 1, 2024 | globenewswire.comAkari Therapeutics Plc: Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024April 15, 2024 | finanznachrichten.deAkari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024April 15, 2024 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Lower in Friday TradingApril 12, 2024 | msn.comDindin lethal in Akari’s disposal of Capital1April 12, 2024 | msn.comAkari Therapeutics Insider Ups Holding By 69% During YearApril 1, 2024 | finance.yahoo.comAkari Therapeutics Reports Full-Year 2023 Financial Results and Recent HighlightsApril 1, 2024 | globenewswire.comPVL: Fifi Sharma, Ced Domingo power Akari romp of NxledMarch 17, 2024 | msn.comPetri Dish: C4’s deal with Merck KGaA; Boston and California biotechs mergeMarch 7, 2024 | bizjournals.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AKTX, HES, TGAN, NSMarch 6, 2024 | stockhouse.comAKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to ShareholdersMarch 5, 2024 | businesswire.comPVL: Grethcel Soltones, Akari still a work in progressFebruary 27, 2024 | msn.comPVL: Ced Domingo has a quiet Akari debut as she adjusts to new systemFebruary 25, 2024 | msn.comPVL: Cignal turns back Akari to open All-Filipino bidFebruary 24, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday TradingFebruary 16, 2024 | msn.com Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. AKTX Media Mentions By Week AKTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKTX News Sentiment▼0.250.61▲Average Medical News Sentiment AKTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKTX Articles This Week▼41▲AKTX Articles Average Week Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tonix Pharmaceuticals News Today Milestone Pharmaceuticals News Today Coya Therapeutics News Today Eupraxia Pharmaceuticals News Today Nuvectis Pharma News Today Rani Therapeutics News Today Adagene News Today Anixa Biosciences News Today Assertio News Today 23andMe News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
